Pomalidomide
Pomalidomide structure
|
Common Name | Pomalidomide | ||
|---|---|---|---|---|
| CAS Number | 19171-19-8 | Molecular Weight | 273.244 | |
| Density | 1.6±0.1 g/cm3 | Boiling Point | 582.9±45.0 °C at 760 mmHg | |
| Molecular Formula | C13H11N3O4 | Melting Point | 318.5 - 320.5° | |
| MSDS | Chinese USA | Flash Point | 306.3±28.7 °C | |
|
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.
Blood Cancer J. 5 , e312, (2015) Immunomodulatory drugs (IMiDs) thalidomide, lenalidomide (Len) and pomalidomide trigger anti-tumor activities in multiple myeloma (MM) by targetting cereblon and thereby impacting IZF1/3, c-Myc and IRF4. Histone deacetylase inhibitors (HDACi) also downregulat... |
|
|
Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects.
J. Clin. Pharmacol. 55(2) , 168-78, (2015) Pomalidomide offers an alternative for patients with relapsed/refractory multiple myeloma who have exhausted treatment options with lenalidomide and bortezomib. Little is known about pomalidomide's potential for drug-drug interactions (DDIs); as pomalidomide ... |
|
|
A validated UPLC-MS/MS assay using negative ionization mode for high-throughput determination of pomalidomide in rat plasma.
J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 983-984 , 76-82, (2015) In this study, a sensitive UPLC-MS/MS assay was developed and validated for high-throughput determination of pomalidomide in rat plasma using celecoxib as an internal standard (IS). Liquid liquid extraction using dichloromethane was employed to extract pomali... |
|
|
Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
J. Hematol. Oncol. 9 , 17, (2016) The polycomb complex protein BMI-1 (BMI-1) is a putative oncogene reported to be overexpressed in multiple myeloma (MM). Silencing of BMI-1 was shown to impair the growth and survival of MM cells. However, therapeutic agents specifically targeting BMI-1 were ... |
|
|
Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
Cancer Immunol. Immunother. 63(10) , 1023-36, (2014) Multiple myeloma (MM) is characterized by a malignant proliferation of plasma cells in the bone marrow with associated organ damage. Although the prognosis of MM has improved recently, the disease remains incurable for the large majority of patients. The erad... |
|
|
Chlorpyrifos and cypermethrin induce apoptosis in human neuroblastoma cell line SH-SY5Y.
Basic Clin Pharmacol Toxicol. 116(2) , 158-67, (2015) Our previous in vivo studies showed that chlorpyrifos (CPF) and cypermethrin (CM) in a mixture dermally administered, strongly inhibited cholinesterase activity in plasma and the brain and were very toxic to the rat central nervous system. In this work, the m... |
|
|
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
Br. J. Haematol. 171 , 798-812, (2016) The proteasome inhibitor bortezomib is an effective therapy for the treatment of relapsed and refractory multiple myeloma (RRMM); however, prolonged treatment can be associated with toxicity, peripheral neuropathy and drug resistance. Our earlier studies show... |
|
|
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
Leukemia 29(3) , 705-14, (2015) The development of resistance to therapy is unavoidable in the history of multiple myeloma patients. Therefore, the study of its characteristics and mechanisms is critical in the search for novel therapeutic approaches to overcome it. This effort is hampered ... |
|
|
A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
FASEB J. 29 , 4829-39, (2015) The immunomodulatory drug (IMiD) thalidomide and its structural analogs lenalidomide and pomalidomide are highly effective in treating clinical indications. Thalidomide binds to cereblon (CRBN), a substrate receptor of the cullin-4 really interesting new gene... |
|
|
A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
J. Manag. Care. Spec. Pharm. 21 , 1134-43, (2015) Given the multiple limitations associated with relatively homogeneous preapproval clinical trials, inadequate data disclosures, slow reaction times from regulatory bodies, and deep-rooted bias against disclosing and publishing negative results, there is an ac... |